Videos

Neurology News Network for the week ending September 5th, 2026. [WATCH TIME: 5 minutes]

Agitation eventually affects nearly every patient with Alzheimer's disease, yet it rarely looks like simple aggression. The panel outlines how common it is, the many forms it takes, and why it so often goes unrecognized.

Distinguishing agitation from depression, anxiety, and psychosis shapes everything that follows in treatment. The panel walks through the clinical differences and where formal screening scales genuinely fit into daily practice.

The neurologist at the UCSF Edward and Pearl Fein Memory and Aging Center discusses how the first platform trial in progressive supranuclear palsy could accelerate the evaluation of potential disease-modifying therapies. [WATCH TIME: 4 minutes]

In this initial segment, epileptologist Jacqueline French, MD, discusses the often-overlooked burdens of epilepsy, including the anxiety of unpredictable seizures, mortality risk, and the demands of maintaining consistent treatment. For people with epilepsy, disease burden cannot be fully captured by counting seizures. The possibility that a seizure could occur without warning can affect how patients approach work, relationships, independence, and everyday activities, creating a persistent psychological burden even during periods when seizures are relatively infrequent.

Neurology News Network for the week ending August 29th, 2026. [WATCH TIME: 5 minutes]

The vice president of Neuroscience and Vaccines at Takeda discusses the clinical significance of oveporexton's FDA approval and how restoring orexin signaling may reshape treatment expectations in narcolepsy type 1.

Explore how a growing understanding of B-cell biology is reshaping treatment strategies in MG and NMOSD, with increasing attention to earlier use of targeted therapies.

The treatment landscape for chronic inflammatory demyelinating polyneuropathy has changed considerably over the past several years, with targeted therapies expanding the options available to clinicians beyond traditional immunomodulatory approaches.

The Stewart J. Greenebaum Endowed Professor in Stroke Neurology at University of Maryland discussed the unmet needs in secondary stroke prevention. [WATCH TIME: 5 minutes]

Neurology News Network for the week ending August 22nd, 2026. [WATCH TIME: 6 minutes]

The final episode covers the practical considerations of implementing doxecitine and doxribtimine in clinical practice, emphasizing early diagnosis, multidisciplinary care, and the next frontier of TK2 deficiency research.

The chief of neurology at Nemours Children’s Health outlined the specialties that may be essential to comprehensive care for patients with spinal muscular atrophy. [WATCH TIME: 5 minutes]

As new therapies enter clinical practice, the questions clinicians ask often shift from whether a treatment works to how it can be used most effectively in the patients they see every day.

Neurology News Network for the week ending August 15th, 2026. [WATCH TIME: 4 minutes]

In the final episode, Yogesh Shah, MD, MPH, FAAFP, details how Alzheimer biomarkers have evolved and why blood-based testing could move the field toward earlier detection, risk reduction, and ultimately prevention.

Neurologist Michio Hirano, MD, reviews the safety profile of doxecitine and doxribtimine, discussing common adverse events, dose management strategies, and practical considerations for monitoring patients with TK2 deficiency.

Yogesh Shah, MD, MPH, FAAFP, discusses how earlier identification of Alzheimer pathology with P-tau217 could change the patient journey, from treatment opportunities to long-term planning and dementia risk reduction.

For clinicians treating chronic inflammatory demyelinating polyneuropathy, numerical improvements on disability scales ultimately matter only if they translate into better function for patients.

The director of neurology at Cook Children's Hospital discusses overlooked challenges in transitioning patients with Lennox-Gastaut syndrome from pediatric to adult care, including insurance changes, mobility concerns, and long-term care planning. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending August 8th, 2026. [WATCH TIME: 4 minutes]

Episode 4 of this Special Report covers the key efficacy findings supporting doxecitine and doxribtimine, highlighting how improvements in survival, motor milestones, respiratory function, and swallowing translate into meaningful clinical benefits for patients with TK2 deficiency.

The associate professor of neurology at Duke University School of Medicine discussed a multicenter initiative studying gut-brain communication in Parkinson disease. [WATCH TIME: 4 minutes]

While primary end points often determine whether a clinical trial meets its objectives, secondary and post hoc analyses frequently provide the clinical context that physicians need to apply those findings in practice.

In this episode, Dr. Yogesh Shah, MD, explores the practical implications of P-tau217 noninferiority and why broader access to blood-based testing could transform Alzheimer's diagnosis.

Dr. Yogesh Shah, MD, reviews the evidence supporting P-tau217 as a reliable rule-in biomarker for Alzheimer's pathology and discusses how clinicians can incorporate blood-based testing into patient evaluation.

As research expands beyond amyloid and tau, experts discuss how novel biomarkers could identify multiple coexisting neurodegenerative pathologies and pave the way for more personalized treatment approaches based on each patient’s unique disease profile. [WATCH TIME: 9 Minutes]

Neurology News Network for the week ending August 1st, 2026. [WATCH TIME: 5 minutes]

In Episode 2 of Neuromuscular Insights with UCSF, host Pritikanta Paul, MD, MBBS, is joined by Miriam Freimer, MD, an expert in neuromuscular medicine, to discuss individualized treatment strategies, therapeutic sequencing, and future directions in the management of generalized myasthenia gravis.

As research moves toward treating Alzheimer disease before symptoms emerge, experts highlight the potential of plasma biomarkers to identify at-risk individuals, guide clinical trial enrollment, and create a window for intervention before irreversible neuronal damage occurs. [WATCH TIME: 6 Mintes]